Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Phase 2 Recruiting
151 enrolled
Frontline Oral Arsenic Trioxide for APL
Phase 2 Recruiting
100 enrolled
IC-APL2020
Phase 2 Recruiting
115 enrolled
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Phase 2 Recruiting
89 enrolled
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Phase 2 Completed
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Phase 2 Completed
78 enrolled 8 charts
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
Phase 2 Unknown
60 enrolled
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
54 enrolled 10 charts
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Phase 2 Completed
17 enrolled 8 charts
AIDA 2000 Guidelines
Phase 2 Unknown
600 enrolled
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Completed
29 enrolled 11 charts
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 15 charts
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
42 enrolled
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
Phase 2 Completed
78 enrolled 10 charts
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Phase 2 Withdrawn
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Phase 2 Terminated
6 enrolled 8 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase 2 Completed
197 enrolled 8 charts
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
Phase 2 Completed
51 enrolled
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Terminated
1 enrolled 4 charts
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Completed
47 enrolled
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Phase 2 Withdrawn
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
Phase 2 Completed
47 enrolled 9 charts
ASCT for Relapsed APL After Molecular Remission
Phase 2 Terminated
5 enrolled
Vorinostat in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
37 enrolled 11 charts
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
PIAPL
Phase 2 Unknown
30 enrolled
High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission
Phase 2 Completed
45 enrolled
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
Phase 2 Completed
40 enrolled
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Phase 2 Completed
STAR-1
Phase 2 Completed
15 enrolled
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
35 enrolled
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Phase 2 Completed
24 enrolled 13 charts
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
280 enrolled
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
Phase 2 Terminated
60 enrolled
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Phase 2 Completed
13 enrolled
Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS
Phase 2 Completed
42 enrolled
Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
Phase 2 Unknown
65 enrolled